ESR1 and breast cancer: To address this gap, we conducted a multicenter, medical record review study to determine whether women with HER2(−)/ER+ pN1mi breast cancer who have low (<18) Recurrence Score results are given adjuvant chemotherapy in a lower proportion than those with high Recurrence Score result (≥31).